Clinical Significance of Intraductal Carcinoma of the Prostate After High-Dose Brachytherapy With External Beam Radiation Therapy: A Single Institution Series and an Updated Meta-Analysis.

Autor: Keiichiro Miyajima, Shun Sato, Naoki Uchida, Hirotaka Suzuki, Kosuke Iwatani, Yu Imai, Koichi Aikawa, Takafumi Yanagisawa, Shoji Kimura, Kojiro Tashiro, Shunsuke Tsuzuki, Mariko Honda, Yusuke Koike, Jun Miki, Kenta Miki, Tatsuya Shimomura, Steffi Yuen, Yuta Yamada, Manabu Aoki, Hiroyuki Takahashi
Předmět:
Zdroj: Clinical Genitourinary Cancer; Apr2024, Vol. 22 Issue 2, p149-156.e1, 9p
Abstrakt: Intraductal carcinoma of the prostate (IDC-P) has been recognized as an adverse pathological feature of prostate cancer (PCa). We performed a retrospective analysis of 138 patients with clinically high-risk, very high-risk, or locally advanced PCa who received high-dose-rate brachytherapy with external beam radiation therapy, elucidating a significant association between the presence of IDC-P and a higher incidence of disease progression. Background: We compared oncological outcomes between prostate cancer (PCa) patients with and without intraductal carcinoma of the prostate (IDC-P) after high-dose-rate brachytherapy (HDR-BT) with external beam radiation therapy (EBRT). Methods: We performed a retrospective analysis of 138 patients with clinically high-risk, very highrisk, or locally advanced PCa who received HDR-BT with EBRT. Of these, 70 (50.7 %) patients were diagnosed with IDC-P; 68 (49.3 %) patients with acinar adenocarcinoma of prostate. The oncological outcomes, including biochemical recurrence-free survival (BCRFS) and clinical progression-free survival (CPFS), were assessed using Kaplan-Meier curves. Additionally, Cox proportional hazards models were used to identify significant prognostic indicators or biochemical recurrence (BCR). Meta-analysis of existing literatures was performed to evaluate the risk of BCR in patients with IDC-P after radiation therapy, compared to those without IDC-P. Results: Kaplan-Meier curves demonstrated significantly inferior BCRFS and CPFS in patients with IDC-P. Multivariate analysis revealed that IDC-P and Grade Group 5 status were associated with increased BCR risk. in our meta-analysis, IDC-P was associated with BCR (HR = 2.13, P = .003). Conclusion: Amongst the patients who received HDR-BT, patients with IDC-P displayed significantly more rapid disease progression, compared with patients who did not have IDC-P. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz: